Fri.May 24, 2024

article thumbnail

Latest Ozempic results 'move the needle' for treating patients with diabetes, chronic kidney disease: Novo exec

Fierce Pharma

While it’s hard to overstate the success Novo Nordisk’s GLP-1 franchise has already achieved, the company’s latest deep dive into semaglutide data in chronic kidney disease (CKD) could help set a n | Early Friday, Novo shared full, positive results from the FLOW trial assessing the ability of once-weekly semaglutide 1.0 mg to help combat major kidney outcomes such as kidney failure, loss of kidney function and death from kidney or cardiovascular causes in people with Type 2 diabetes and chronic

Patients 318
article thumbnail

Why Allegheny Health Network Created Its Own Chat-GPT For Employees

MedCity News

Allegheny Health Network rolled out a large language model designed exclusively for use by its staff members. You can think of the tool as the health system’s own version of Chat-GPT, said Ashis Barad, AHN’s chief digital and information officer. The post Why Allegheny Health Network Created Its Own Chat-GPT For Employees appeared first on MedCity News.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Even after sharp sales drop, Pfizer sees bright side with priority review voucher from Paxlovid approval

Fierce Pharma

In a change of pace from the recent COVID-related business struggles for Pfizer, the drugmaker has picked up a valuable reward from the FDA in the form of a priority review voucher (PRV). | The FDA awarded the voucher based on Paxlovid's status as a countermeasure to a material medical threat, according to a notice in the Federal Register.

FDA 291
article thumbnail

ASCO: AffyImmune claims a first with CAR-T for solid tumours

pharmaphorum

AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy. The case comes from a phase 1 study of its ICAM-1 targeting CAR-T autologous candidate AIC100 in patients with relapsed/refractory poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC), which will be reported at the ASCO congress next week.

Patients 106
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Fierce Pharma Asia—AstraZeneca eyes China's innovation, plots Singapore ADC plant; FDA rejects Hengrui's PD-1 drug

Fierce Pharma

AstraZeneca's CEO wants to tap into China's innovation explosion. The company inked an oncology antibody deal with Harbour BioMed, and it plans to build a $1.5 billion ADC plant in Singapore. | AstraZeneca's CEO wants to tap into China's innovation explosion. The company inked an oncology antibody deal with Harbour BioMed, and it plans to build a $1.5 billion ADC plant in Singapore.

FDA 188
article thumbnail

New Phase III data for hidradenitis suppurativa biologic released

European Pharmaceutical Review

UCB has announced positive results from the first Phase III trials evaluating the efficacy and safety of an IL-17A and IL–17F inhibitor to treat adults with moderate-to-severe hidradenitis suppurativa. Humanised IgG1 monoclonal antibody (mAb) BIMZELX ® (bimekizumab-bkzx) selectively binds to IL-17A, IL-17F, and IL-17AF cytokines. This inhibits their interaction with the IL-17RA/IL-17RC receptor complex, UCB explained.

More Trending

article thumbnail

ADC developer Pheon raises $120m, and other bio financings

pharmaphorum

This week’s round-up of biotech financings is led by a $120 million round for UK-based antibody-drug conjugate (ADC) developer Pheon, with SixPeaks also pulling in nine figures and smaller rounds for Progentos, LabGenius, and Grey Wolf, and Imvax.

96
article thumbnail

Next-Generation Nursing

MedCity News

Virtual observation programs can help improve care, help better staff units, and help give nurses the support they need. The post Next-Generation Nursing appeared first on MedCity News.

102
102
article thumbnail

FDA advisory committee reviews Novo Nordisk insulin icodec for T1D

Pharmaceutical Technology

The US FDA's EMDAC is set to hold a meeting to assess the benefit-risk profile of Novo Nordisk's insulin icodec, to treat type 1 diabetes.

FDA 98
article thumbnail

Lyra Health Announces Mental Health Offering for Teens

MedCity News

Lyra Care for Teens will be available starting in June. Patients will gain access to therapists who specialize in evidence-based treatments and personalized digital lessons. The post Lyra Health Announces Mental Health Offering for Teens appeared first on MedCity News.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Merck KGaA Announces $600 Million Deal to Acquire Mirus Bio

PharmaTech

With this acquisition, Merck KGaA will have the capability to offer integrated services for viral vector manufacturing.

article thumbnail

NICE, NHS England unveil new pathway for medtech

pharmaphorum

NICE and NHS England are seeking feedback on proposed new rules and commissioning principles for medtech products.

100
100
article thumbnail

King’s Doctoral Training Centre to investigate MS symptom management

PharmaTimes

The lifelong autoimmune disease affects more than 150,000 people living in the UK

Doctors 112
article thumbnail

ASCO: Merus bispecific garners attention after abstract drop

pharmaphorum

Shares in Merus spike on ASCO abstract on phase 2 trial of EGFRxLGR5 bispecific petosemtamab in head and neck cancer.

96
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Eli Lilly Pumps $5.3B More Into Site for Making Metabolic Meds Zepbound & Mounjaro

MedCity News

Eli Lilly says its capital commitment to its new Indiana site is the largest manufacturing investment in the company’s history. The site will make tirzepatide, the active pharmaceutical ingredient in both Zepbound and Mounjaro. The post Eli Lilly Pumps $5.3B More Into Site for Making Metabolic Meds Zepbound & Mounjaro appeared first on MedCity News.

article thumbnail

Agenda announced for FlyPharma Vienna 2024

PharmaTimes

The conference will take place on 23 to 24 October at Vienna AirportCity

article thumbnail

ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody

Pharmaceutical Technology

Shares in Merus rose by 15% in premarket trading, following the announcement of positive Phase II data to be presented at ASCO.

72
article thumbnail

7 Tips for Providers to Improve Appointment Form Conversion Rates

Penrod

An online booking platform enables patients to schedule medical appointments efficiently and conveniently, alleviating the workload on your front office. However, merely having an online presence might not suffice in today’s competitive healthcare market. Your appointment forms likely need optimization. Improving your existing forms with a focus on conversion rates can lead to more patients and growing revenue.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

A Day At The Medalist: Where Vision, Mindset, and Grit Met on the Golf Course

Scott Burrows

A few weeks ago, I had the incredible opportunity to tee off at the prestigious Medalist Golf Club in Jupiter, Florida. As I made my way down the manicured fairways and navigated the challenging greens, I couldn’t help but feel a sense of awe knowing that I was playing on the same course frequented by golf legends like Tiger Woods and Rory McIlroy.

article thumbnail

9 Patient Intake Mistakes Healthcare Providers Make During Acquisition

Penrod

1. Inefficient Appointment Scheduling An inefficient appointment scheduling system can lead to long wait times, double booking, and limited appointment availability, frustrating your existing and potential patients. These issues can disrupt the flow of your practice, causing dissatisfaction and potentially leading to a loss of patients. To solve this problem, you need a comprehensive booking system that offers consistency at each intake location.

article thumbnail

Therapy reprogrammes immune cells to shrink prostate and bladder cancers

PharmaTimes

JHU083 reduced tumour growth and triggered tumour cell death in mice

85
article thumbnail

Biogen to Acquire HI-Bio in Deal Worth Potentially Up to $1.8 Billion

PharmaTech

With the acquisition, Biogen gains felzartamab, HI-Bio's lead investigational mAb candidate being developed for the treatment of a range of immune-mediated diseases.

Leads 52
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

EC approves Celltrion’s Omlyclo for allergic conditions

Pharmaceutical Technology

The EC has approved Celltrion’s Omlyclo, an omalizumab biosimilar for reference product Xolair to treat allergic conditions.

59
article thumbnail

Degron Therapeutics, Takeda Ink Exclusive License and Collaboration Agreement to Develop Molecule Degraders Targeting Multiple Indications

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52
article thumbnail

ASCO 2024: MediLink’s NSCLC and breast cancer ADC shows early safety success

Pharmaceutical Technology

The clinical-stage biotech will share preliminary safety and efficacy data with its ADC at the 2024 ASCO meeting.

Safety 59
article thumbnail

Cityblock Health Announces Further Partnerships with Centene Corporation to Bring Value-Based Healthcare to Florida

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Grey Wolf gains $50m boost for antigen modulation tech

Pharmaceutical Technology

Grey Wolf Therapeutics has concluded an oversubscribed $50m in Series B financing expansion to advance its antigen modulation technology.

52
article thumbnail

Pharma Pulse 5/24/24: Counsel Patients on Nutrition and Following a Balanced Diet Complementary to GLP-1s, Neuralink’s First Brain-Implant Patient Stays Upbeat & more

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

article thumbnail

Cystic fibrosis: global clinical trials landscape and treatments

Pharmaceutical Technology

Affecting more than 162,000 patients worldwide, global clinical trials are researching innovative new treatments for cystic fibrosis.

article thumbnail

Study Finds Semaglutide Improves Chronic Kidney Disease in Patients With Type 2 Diabetes

Pharmacy Times

The role of semaglutide as a glucagon-like peptide-1 (GLP-1) receptor antagonist could offer further treatment options to improve patient outcomes.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A